Olaparib [120] and other PARP inhibitors, such as niraparib [121] or talazoparib [122], have demonstrated promising results also in the neoadjuvant setting for HER2-negative BRCA-mutated early BC, although no significant difference has been observed in terms of pCR between using PARP inhibitors alone or in combination with chemotherapy [123]. This evidence concerns the gene ERBB2 and breast cancer.